Gilead to present 18-month anito-cel trial follow-up data in multiple myeloma at ASH 2026
GILD•GILD•GILD•GILD•Gilead Sciences and Kite will present 23 abstracts, including updated pivotal Phase 2 anito-cel results, at ASH on December 12-15, 2026; the FDA decision target date for the anito-cel application is December 23, 2026.
Gilead Sciences and Kite plan to present 23 abstracts, including seven oral presentations, at the American Society of Hematology meeting on December 12-15, 2026. Updated pivotal Phase 2 anito-cel results will assess survival and safety in heavily pretreated patients with relapsed or refractory multiple myeloma.
The anito-cel study supports a U.S. marketing application under FDA review, with a decision target date of December 23, 2026. Presentations will also include five-year Yescarta follow-up in first-line high-risk large B-cell lymphoma and initial clinical findings for investigational gamgertamig in relapsed or refractory autoimmune cytopenias.
